4.2 Review

Clinical consequences of ADR beta 2 polymorphisms

期刊

PHARMACOGENOMICS
卷 9, 期 3, 页码 349-358

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/14622416.9.3.349

关键词

-

向作者/读者索取更多资源

The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADR beta 2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ADR beta 2 variations Gly(16)Arg and Gln(27)Glu and, more recently, haplotypic variations, have been the focus of numerous pharmacogenetic studies looking at responses to short-acting (SABA) and long-acting beta-agonists (LABA) in subjects with asthma. Thus far, a consensus on the effects of ADR beta 2 genetic variations has not been reached, although there does appear to be a reproducible adverse effect in subjects homozygous for Arg(16) that are regularly treated with SABAs. The complexity of the genotype by response effects observed makes clinical application of ADR beta 2 genetic variations limited, and may require the use of detailed haplotypic variation to fully understand the role ADR beta 2 plays in regulating beta-agonist response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据